R2 Technology launches its second-generation ImageChecker CT Lung computer-aided detection system

Sunnyvale 17 May 2005R2 Technology Inc., specialized in computer-aided detection (CAD) technology for earlier detection of breast cancer, has launched its ImageChecker CT Lung Version 2.0 CAD software system and AutoPoint temporal comparison feature for use during review of multi-slice CT (MSCT) chest exams. This second-generation software is designed to maximize physician accuracy and efficiency in finding actionable lung nodules early - when treatment can be most effective - and tracking nodule changes over time. The new system also features expanded PACS integration for increased work flow efficiency. The ImageChecker CT Lung Version 2.0 CAD software system and AutoPoint temporal comparison tool will soon be made available as the only CT Lung CAD option integrated into the Vitrea workstation's CT Lung visualization package, developed by Vital Images Inc.


"Our ImageChecker CT Lung CAD system serves as a second set of eyes to physicians and increases their accuracy and efficiency when reviewing the enormous number of images produced by a multi-slice CT chest study", stated John Pavlidis, president and chief executive officer of R2 Technology. "Now, with its expanded PACS integration and ability to accurately track nodule growth over time - a key measure of lesion significance - our CAD system can further increase physicians' accuracy and productivity, thus benefiting their patients and saving time." Mr. Pavlidis noted that the ImageChecker CT Lung CAD system benefits from the same focus on quality and ease of use that have established R2 Technology's CAD algorithm as the gold standard in mammography.

R2 Technology's CT Lung CAD system is the only solution of its kind approved by the U.S. Food and Drug Administration (FDA) under its rigorous Pre-Market Approval process. Clinical research submitted to the FDA showed that the ImageChecker CT Lung CAD system reduced the number of actionable lung nodules missed by radiologists by 26 percent, with a false marker rate of only two per normal case. The FDA approved the conclusion that the ImageChecker CT Lung CAD software system showed a statistically significant average reader improvement (p=0.003) for detection of solid pulmonary nodules (4mm-30mm).

The new Version 2.0 software features enhancements to R2's CT Lung CAD algorithm. Version 2.0 also enables CAD results to be sent to PACS systems using standard formats for enterprise-wide accessibility. Additionally, the AutoPoint temporal comparison option uses automatic 3D registration to enable physicians to automatically and accurately track nodule changes over time despite variability between scans. The system also provides a tabular report featuring key images and information on nodule volume and density changes, as well as a nodule's estimated growth doubling time, an important measure of the likelihood of the nodule being malignant.

"Radiologists look at hundreds of images on each multi-slice chest CT study. R2 Technology's first foray into lung CAD has added to our confidence in our interpretations, ensuring that we are detecting as many relevant lung nodules as early as possible. The thoughtfully-designed, intuitive, easy to use interface has made this technology a pleasure to utilize on a daily basis. We have just received an upgrade to version 2.0 of the ImageChecker CT Lung CAD system and were excited to see the addition of spatially registered temporal comparison, incremental improvements to the interface permitting easy integration with our PACS system, and other features. All of this helps our efforts to optimize clinical outcomes for our patients", stated David S. Mendelson, M.D., Associate Professor of Radiology at the Mount Sinai School of Medicine in New York City.

According to the World Health Organization and the American Cancer Society (ACS), lung cancer is one of the world's most common cancers, accounting for 1,2 million cases annually worldwide and 31 percent of estimated annual cancer deaths in United States men and 27 percent of cancer deaths in United States women. Lung cancer, often presenting as small nodules, can be difficult to detect in its early stages. The ACS reports that the five-year survival rate in the United States for all stages of lung cancer was 15 percent. If lung cancer is found and treated while it is localized, however, the ACS reports that survival rates increase to 49 percent. Unfortunately, at present, only about 16 percent of lung cancers are found in the early stages.

R2 Technology Inc., headquartered in Sunnyvale, California, is a recognized leader in the development and commercialization of computer-aided detection (CAD), an innovative technology that assists radiologists in the earlier detection of breast cancer, actionable lung nodules and other lung abnormalities. As a medical software company, R2 Technology is developing CAD systems for a variety of imaging modalities and disease states. R2 recently received an "A" rating from MD Buyline and was given the Frost and Sullivan Product Leadership Award. More company news is can be found in the VMW January 2004 article R2's Universal Breast Imaging Workstation and MeVis BreastCare's soft-copy reading software support advanced CAD applications.

Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]